ストックスクリーナーアプリを入手
26.02
1.03%
-0.27
アフターアワーズ：
25.85
-0.17
-0.65%
Beam Therapeutics Inc (BEAM) 最新ニュース
Beam Therapeutics (BEAM) insider Amy Simon plans sale of 16,677 common shares - Stock Titan
Beam Therapeutics (BEAM) Revenue BreakdownMain Composition - Moomoo
TradingKey - TradingKey
Beam Therapeutics Inc (BEAM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Beam Therapeutics Inc (BEAM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BEAM|Beam Therapeutics Inc|Price:25.100|Chg%:-0.810 - TradingKey
Beam Therapeutics Inc (BEAM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Beam Therapeutics Inc (BEAM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Beam Therapeutics Inc. (BEAM) stock price, news, quote and history - Yahoo Finance Australia
First Trust Heitman Glbl Prm Rl Estt ETF (PRME) stock price, news, quote and history - Yahoo Finance UK
Beam Therapeutics Inc (BEAM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Beam Therapeutics Inc. (BEAM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Beam Therapeutics to present BEAM-302 data at September conference By Investing.com - Investing.com Nigeria
Beam Therapeutics to present BEAM-302 data at September conference - Investing.com
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 - The Manila Times
Beam's One-Time Alpha-1 Treatment Data Update Set for Sept. 8 - Stock Titan
Beam Therapeutics Stock 9-Day Losing Spree: Stock Falls 31% - Trefis
9 Red Days In A Row: Beam Therapeutics Stock Is Down 31% - Trefis
8 Red Days In A Row: Beam Therapeutics Stock Is Down 27% - Trefis
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? - The Motley Fool
ETFs Investing in Beam Therapeutics, Inc. Stocks - TradingView
8-Day Sell-Off Sends Beam Therapeutics Stock Down 27% - Trefis
Understanding the Setup: (BEAM) and Scalable Risk - Stock Traders Daily
BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits
Beam Therapeutics Stock 6-Day Losing Spree: Stock Falls 19% - Trefis
6 Red Days In A Row: Beam Therapeutics Stock Is Down 19% - Trefis
Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM) - Yahoo Finance
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics - Yahoo Finance
4 Best CRISPR Companies to Buy in 2026 and How to Invest - The Motley Fool
BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
What Were the Key Highlights from Beam's RBC Conference Presentation - Kavout | AI
Prime Medicine gains after winning arbitration with Beam Therapeutics - MSN
Beam Therapeutics Inc. (BEAM) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Beam Therapeutics (BEAM) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically? - Yahoo Finance
Prime Editing Clears IP Fight, Sets Q3 Filing for First Liver-Targeted AATD Drug - Tech Times
Prime Medicine Beats Beam Therapeutics In Patent DisputeBut Both Are Investable (PRME) - Seeking Alpha
BofA Securities Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $47 - Moomoo
BEAM Reiterated by B of A Securities -- Price Target Maintained at $47 - GuruFocus
Prime Medicine Jumps 15% as Arbitration Win Clears Path for AATD Gene-Editing Human Trials - finance.biggo.com
TD Cowen reiterates Buy on Prime Medicine stock after arbitration win By Investing.com - Investing.com South Africa
Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise - marketscreener.com
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case - Benzinga
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug - Stocktwits
BofA reiterates Beam Therapeutics stock rating after arbitration ruling By Investing.com - Investing.com Nigeria
BofA reiterates Beam Therapeutics stock rating after arbitration ruling - Investing.com
Prime Medicine wins binding arbitration against Beam Therapeutics - grafa.com
Prime Medicine stock surges after winning arbitration with Beam By Investing.com - Investing.com South Africa
Why is Beam Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics - The Manila Times
Prime Medicine (NASDAQ: PRME) cleared of breach in Beam arbitration ruling - Stock Titan
0.54%
2.87%
大文字化:
|
ボリューム (24 時間):